


MICI : nouvelles idées nouvelles thérapeutiques

Guillaume Savoye


Les MICI sont des maladies progressives...



CDAI, Crohn's disease activity index; CDEIS, Crohn's disease endoscopic index of severity; CRP, C-reactive protein

Pariente B, ... Lemann M. Inflamm Bowel Dis 2011; Colombel JF et al. Gastroenterology 2017


Qu'il faut traiter précocément...



CDAI, Crohn's disease activity index; CDEIS, Crohn's disease endoscopic index of severity; CRP, C-reactive protein

Pariente B, ... Lemann M. Inflamm Bowel Dis 2011; Colombel JF et al. Gastroenterology 2017

Pour éviter la destruction intestinale et l'invalidité associée




CDAI, Crohn's disease activity index; CDEIS, Crohn's disease endoscopic index of severity; CRP, C-reactive protein

Pariente B, et al. Inflamm Bowel Dis 2011; Colombel JF et al. Gastroenterology 2017


Pariente B, et al. Inflamm Bowel Dis 2011;17:1473-22

les anti-TNF rapidement diminuent la destruction intestinale

- 130 Crohn
 - Score de destruction intestinale



CD, Crohn's disease; IQR, interquartile range





Farre C, et al. Presented at UEG Week 2017


La cible dans les MICI

Rémission clinique

+




“le contrôle serré”





CDAI, Crohn's disease activity index; CDEIS, Crohn's disease endoscopic index of severity; CRP, C-reactive protein

Pariente B, et al. Inflamm Bowel Dis 2011; Colombel JF et al. Gastroenterology 2017



Etude CALM ou décider sur des biomarqueurs...




On fait mieux en prenant en compte les biomarqueurs en plus de la clinique...



Place de l'imagerie “proactive” dans le monitoring




Des nouvelles cibles...



IL, interleukin.

Adapted from Danese S, Gut 2012 and Torres J et al. Lancet 2017


IL-12 and IL-23 et Crohn




Ustekinumab et Crohn

Réponse à 6 semaines

UNITI-1




UNITI-2



AMM: Bolus iv

Feagin B et al. NEJM 2016

Ustekinumab et Crohn: rémission à la 44^{ie} semaine




AMM: entretien sc toutes les 8 ou 12 semaines



Feagn B et al. NEJM 2016

Vedolizumab = Entyvio®

– Anti intégrine $\alpha 4\beta 7$



Inhibition spécifique
interaction
 $\alpha 4\beta 7$ /MADCAM1



• Entyvio® = Vedolizumab

AMM

et remboursement : RCH et Crohn


AMM

et remboursement : RCH et Crohn


Voie intraveineuse

Induction puis entretien 300 mg/8S


RCH S52



MC S6




MC S52



Feagan BG, *N Engl J Med* 2013;369(8):699–710
Sandborn WJ, *N Engl J Med* 2013;369:711–721.

L'arrivée des petites molécules par voie orale




Spadaccini M, et al. Int. J. Mol. Sci. 2017, 18, 1276

Sandborn WJ, et al. N Engl J Med 2016;374:1754–1762

Peyrin-Biroulet L, et al. Autoimmun Rev 2017;16:495–503.

Tofacitinib, inhibiteur panJAK: Phase III dans la RCH





Nom commercial Xeljanz

AMM et remboursement dans la PR

Sandborn W, et al. N Engl J Med 2017;376:1723–1736

Nouvelles approches : cellules souches

Des cellules souches d'origine graisseuses



conclusion

